Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E

ApprovedActive

0 views this week 0 watching⚡ Active

Interest: 44/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Critical Illness

Conditions

Critical Illness, Starvation

Trial Timeline

Aug 1, 2007 → Dec 1, 2026

NCT ID

NCT00512122

About Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E

Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E is a approved stage product being developed by Baxter for Critical Illness. The current trial status is active. This product is registered under clinical trial identifier NCT00512122. Target conditions include Critical Illness, Starvation.

What happened to similar drugs?

3 of 8 similar drugs in Critical Illness were approved

Approved (3) Terminated (2) Active (3)

✅DaptomycinMerckApproved

✅Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months.AmgenApproved

🔄Apixaban + ASA + Clopidogrel 75mgPfizerPhase 3

✅Colchicine (Colcrys®) + placebo + allopurinolRegeneron PharmaceuticalsApproved

🔄Rilonacept 80 mg + Rilonacept 160 mgRegeneron PharmaceuticalsPhase 3

❌Remodulin® (treprostinil sodium) InjectionUnited TherapeuticsPhase 3

❌Olimel (5.7%E / N9E)BaxterPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00512122	Approved	Active	Aug 1, 2007	Dec 1, 2026	Critical Illness

Competing Products

13 competing products in Critical Illness

See all competitors

Product	Company	Stage	Hype Score
Daptomycin	Merck	Approved	43
Ceftolozane/Tazobactam - Multiple Doses + Ceftolozane/Tazobactam - Single Dose	Merck	Phase 1	29
Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months.	Amgen	Approved	39
intensive insulin therapy to maintain normoglycemia	Novo Nordisk	Phase 2	35
Midazolam + Dexmedetomidine	Pfizer	Pre-clinical	26
Apixaban + ASA + Clopidogrel 75mg	Pfizer	Phase 3	36
Colchicine (Colcrys®) + placebo + allopurinol	Regeneron Pharmaceuticals	Approved	43
Rilonacept 80 mg + Rilonacept 160 mg	Regeneron Pharmaceuticals	Phase 3	40
treprostinil dienthanolmine sustained release + Placebo	United Therapeutics	Phase 2	32
Remodulin® (treprostinil sodium) Injection	United Therapeutics	Phase 3	29
Olimel (5.7%E / N9E)	Baxter	Phase 3	29
RJX + Placebo	ICON plc.	Phase 1	26
Ixmyelocel-T	Vericel	Phase 3	34